CAJ | 학술논문

目的：测定我院临床分离的耐甲氧西林金黄色葡萄球菌（ MRSA）对利奈唑胺与克林霉素的体外抗菌活性。方法用微量肉汤稀释法，测定抗菌药物的最低抑菌浓度（ MIC ）和最低杀菌（ MBC ）浓度。结果利奈唑胺在浓度为2μg· mL-1时的抑菌率为100％，而克林霉素抑菌率为100％时浓度为32μg· mL-1。利奈唑胺对 MRSA 的 MIC 为0.25~2.00μg · mL-1， MIC50为1μg· mL-1，MIC90为2μg · mL-1， MBC50和 MBC90分别为8μg · mL-1和16μg· mL-1。克林霉素对 MRSA 的 MIC 为0.25~32μg · mL-1， MIC50为16μg· mL-1，MIC90为32μg · mL-1， MBC50和 MBC90分别为32μg · mL-1和>64μg· mL-1。结论克林霉素在治疗MRSA感染或疑似MRSA感染时要以药敏结果为依据，而利奈唑胺用于MRSA感染或疑似MRSA感染的治疗时可靠性更高。
목적：측정아원림상분리적내갑양서림금황색포도구균（ MRSA）대리내서알여극림매소적체외항균활성。방법용미량육탕희석법，측정항균약물적최저억균농도（ MIC ）화최저살균（ MBC ）농도。결과리내서알재농도위2μg· mL-1시적억균솔위100％，이극림매소억균솔위100％시농도위32μg· mL-1。리내서알대 MRSA 적 MIC 위0.25~2.00μg · mL-1， MIC50위1μg· mL-1，MIC90위2μg · mL-1， MBC50화 MBC90분별위8μg · mL-1화16μg· mL-1。극림매소대 MRSA 적 MIC 위0.25~32μg · mL-1， MIC50위16μg· mL-1，MIC90위32μg · mL-1， MBC50화 MBC90분별위32μg · mL-1화>64μg· mL-1。결론극림매소재치료MRSA감염혹의사MRSA감염시요이약민결과위의거，이리내서알용우MRSA감염혹의사MRSA감염적치료시가고성경고。
Objective To determinate the antibacterial activity of linezolid and clindamycin agents of clinical methicillin -resistant Staphy-lococcus aureus ( MRSA ) in vitro.Methods The minimum inhibitory concentration ( MIC ) and minimum bactericidal concentration ( MBC ) of antibacterial agents were determined by the micro broth dilution method . Results The linezolid inhibition rate was 100%when the concentration was 2 μg · mL-1 , but clindamycin concentration was 32 μg · mL-1 . The MIC range of linezolid for MRSA was 0.25 ~2.00 μg · mL-1 , MIC50 was 1 μg · mL -1 , MIC90 was 2 μg · mL-1 , MBC50 was 8 μg· mL-1 , MBC90 was 16 μg· mL -1.The MIC range of clindamycin for MRSA was 0.25 ~32.00 μg · mL-1 , MIC50 was 16 μg · mL-1 , MIC90 was 32 μg · mL-1 , MBC50 was 32 μg · mL-1 , MBC90 was >64 μg· mL-1.Conclusion Clindamycin in the treatment of MRSA infection or suspected MRSA infection must depend on drug sensi-tivity test results.Linezolid in the treatment of MRSA infection or suspec-ted MRSA infection has higher reliability .